| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 23.1% YoY consolidated growth; base business grew 18%. |
|---|---|
| Margins | EBITDA margins targeted at 21-22% despite supply chain headwinds. |
| Demand visibility | Strong visibility in India and US respiratory/oncology segments. |
| Management confidence | Confident, focusing on innovation pipeline and branded portfolio expansion. |
Growth
Base business grew 18% excluding deferred income; India outperformed IPM at 15.5% growth while US grew 19.8%.
Outlook
Management maintains FY27 EBITDA margin guidance of 21-22% and expects 12-15% India growth.
Risks
Elevated API and logistics costs due to geopolitical situations threaten near-term gross margin stability.
Earnings Call Transcript filed with NSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,380.00
- Market cap
- ₹67,169 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 37.4×Sector 50.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).
- Call
- Guides 15% growth
Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Glenmark reported strong Q1 FY27 results with consolidated revenue of Rs. 40,185 million, representing 23.1% YoY growth. Strategy focuses on core business strengthening and expanding innovation-led platforms like RYALTRIS®.